Targeting the EGFR and c-Met Tyrosine Kinase Receptors in Myeloproliferative Neoplasms

靶向骨髓增生性肿瘤中的 EGFR 和 c-Met 酪氨酸激酶受体

• 批准号: nhmrc : 1063443
• 负责人: A/Pr Peter Bardy
• 金额: $ 40.51万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-egfr-c-myeloproliferative-neoplasms/455057
• 关键词: Targeting; EGFR; Met; Tyrosine; Kinase

We propose that in the blood disorders called Myeloproliferative Neoplasms (MPN) there are important changes that affect the function of receptors expressed on the surface of blood cells. These changes will perturb blood cell production and may be able to be targeted effectively with drugs. We will test this using laboratory-based and mouse models of MPN, together with specific drugs that are currently in the clinic, and that inhibit the activity of the key receptors involved. This approach can be rapidly translated to clinical trial.

我们提出，在称为骨髓增生性肿瘤（MPN）的血液疾病中，存在影响血细胞表面表达的受体功能的重要变化。这些变化将扰乱血细胞的生产，并可能被药物有效地靶向。我们将使用基于实验室的MPN和小鼠模型，以及目前在临床上的特定药物来测试这一点，并抑制相关关键受体的活性。这种方法可以迅速转化为临床试验。